Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Arla Foods | INDUSTRY |
| Aarhus University Hospital Skejby | OTHER |
Not provided
Not provided
Not provided
Not provided
This study evaluates the cardiovascular effects of adding the ketone body 3-hydroxy butyrate (3-OHB) to whey protein during human endotoxemia. Further, this study compares cardiovascular changes during healthy and catabolic conditions.
Participants will receive isocaloric, isonitrogenous beverages of either whey or 3-OHB+whey in a randomized crossover design during either healthy (overnight fast) or catabolic conditions (inflammation/endotoxemia + 36 h fast and bed rest).
Background: A newly published study found beneficial cardiovascular effects of 3-OHB infusion in a population with chronic heart failure, significantly increasing cardiac output. Similar effects on cardiac output were observed in healthy volunteers. These findings pave the way for 3-OHB as a therapeutic nutritional supplement, since it is well-absorbed during oral consumption. However, it is unknown whether the cardiovascular effects of 3-OHB persist during a sepsis-like catabolic state and when administered orally.
Aim: This study aims to investigate the cardiovascular effects of adding the ketone body 3-hydroxy butyrate (3-OHB) to whey protein during a human disease model, comprising endotoxemia + bed rest + fast.
Hypothesis:
Adding the ketone body 3-OHB to an oral protein supplement increases cardiac output measures
Catabolic stress (endotoxemia/inflammation + 36 h fast and bed rest) induces cardiovascular changes compared with healthy conditions (overnight fast)
Interventions:
In a randomized crossover design, eight healthy, lean, young men will undergo either:
i) Healthy conditions (overnight fast) + whey protein^
ii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest*) + whey protein^
iii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest*) + 3-OHB/whey protein^"
*LPS will be administered (1 ng/kg) the day prior to the study together with fast and bed rest. On the study day LPS (0.5 ng/kg) will be injected.
^Beverages will be isonitrogenous and isocaloric (fat will be added) with 45 g whey protein + 20 g maltodextrin. Bolus/sip administration will be applied (1/3 bolus, 1/2 sip)
" 50 grams of 3-OHB will be orally administered (1/2 bolus, 1/2 sip)
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy + Whey | Experimental | Healthy conditions (overnight fast) |
|
| Catabolic + Whey | Experimental | Catabolic conditions (36-hour fast, bed rest and inflammation (LPS)) |
|
| Catabolic + 3-OHB / Whey | Experimental | Catabolic conditions (36-hour fast, bed rest and inflammation (LPS)) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Whey | Dietary Supplement | 45 g whey + 20 g maltodextrin |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change in left ventricular outflow tract velocity time integral | Echocardiographic changes in left ventricular outflow tract velocity time integral from the basal period and after 1.5 hours of intervention | Measured during the basal period and after 1.5 hours of intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Left Ventricular Ejection Fraction (LVEF) | Echocardiographic changes in LVEF from the basal period and after 1.5 hours of intervention | Measured during the basal period and after 1.5 hours of intervention |
| Changes in Global Longitudinal Strain (GLS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Recent immobilization of an extremity that is not fully rehabilitated
Lactose, lidocain or rubber allergies
Current disease
Use of anabolic steroids
Smoking
Former major abdominal surgery (Or current problems with the GI tract)
•>10 hours of exercise/weak
Present ketogenic diets or high-protein diets
Blood doner that does not want to discontinue blood donations until study completion
Pending MR scan
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Niels Moeller, Professor | Aarhus University Hospital and Institute of Clinical Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical Research Labarotory, DoH, Aarhus University Hospital | Aarhus | 8200 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019446 | Endotoxemia |
| ID | Term |
|---|---|
| D016470 | Bacteremia |
| D018805 | Sepsis |
| D007239 | Infections |
| D014115 | Toxemia |
| D018746 |
Not provided
Not provided
| ID | Term |
|---|---|
| D000067796 | Whey |
| ID | Term |
|---|---|
| D008892 | Milk |
| D001628 | Beverages |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
In a randomized crossover design, eight healthy lean young men will undergo either:
i) Healthy conditions (overnight fast) + whey protein
ii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest) + whey protein
iii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest) + 3-OHB/whey protein
Not provided
Not provided
Interventions (saline/LPS) or whey/3-OHB+whey will be given by the investigator, and the echocardiography will be performed by another blinded investigator.
| 3-OHB + Whey |
| Dietary Supplement |
50 g ketone + 45 g whey + 20 g maltodextrin |
|
Echocardiographic changes in GLS from the basal period and after 1.5 hours of intervention |
| Measured during the basal period and after 1.5 hours of intervention |
| Changes in S´ Max | Echocardiographic changes in S´ Max from the basal period and after 1.5 hours of intervention | Measured during the basal period and after 1.5 hours of intervention |
| Changes in blood pressure | Changes in blood pressure from the basal period and after 1.5 hours of intervention | Measured during the basal period and after 1.5 hours of intervention |
| Changes in heart rate | Changes in heart rate from the basal period and after 1.5 hours of intervention | Measured during the basal period and after 1.5 hours of intervention |
| Changes in axillary temperature | Changes in axillary temperature from the basal period and after 1.5 hours of intervention | Measured during the basal period and after 1.5 hours of intervention |
| Difference in Left Ventricular Ejection Fraction (LVEF) (Healthy vs catabolic conditions) | Echocardiographic difference in LVEF during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure) | Measured after 2 hours of basal period |
| Difference in Global Longitudinal Strain (GLS) (Healthy vs catabolic conditions) | Echocardiographic difference in GLS during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure) | Measured after 2 hours of basal period |
| Difference in S´ Max (Healthy vs catabolic conditions) | Echocardiographic difference in S´ Max during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure) | Measured after 2 hours of basal period |
| Difference in axillary temperature (healthy vs catabolic) | Difference in axillary temperature after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure) | Measured after 2 hours of basal period |
| Difference in heart rate (healthy vs catabolic) | Difference in heart rate after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure) | Measured after 2 hours of basal period |
| Difference in blood pressure (healthy vs catabolic) | Difference in blood pressure after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure) | Measured after 2 hours of basal period |
| Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003611 |
| Dairy Products |
| D005502 | Food |
| D019602 | Food and Beverages |